reports
- Ahmed Ben Salem
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
Aelis Farma : The phase IIb study for AEF0117 failed to reach its prim...
>AEF0117 failed to reach its primary endpoint for phase IIb - We learned this morning of the phase II results for the group’s flagship trial evaluating AEF0117 in patients (n=330) seeking treatment for cannabis use disorder (CUD). The main aim of this study was to show that AEF0117 results in a larger proportion of ‘responders’ (patients with cannabis consumption = 1 day per week) compared to a placebo for patients seeking treatment for moderate to severe CUD, accordi...
- Oscar Haffen Lamm
- Valliant Campagne
Aelis: AEF0117 missed binary endpoints in its phase 2b for CUD
Aelis published this morning AEF0117's phase 2b topline data in CUD, where no statistically significant effects were observed across the binary endpoints, which measured the absolute reduction in cannabis consumption. While the exact data was not communicated, it was reported that in the context an
- Martial Descoutures
- Oussema Denguir
Aelis Farma : La phase 2b d’AEF0117 n’atteint pas son critère primaire
>AEF0117 n’atteint pas son critère primaire de phase 2b - Nous apprenons ce matin les résultats de phase 2 de l’essai phare du groupe évaluant AEF0117 chez les patients (n=330) en recherche de traitement souffrant de troubles liés à la consommation de cannabis (CUD). L'objectif principal de cette étude était de démontrer qu’AEF0117 induit une plus grande proportion de « RÉPONDEURS » (c'est-à-dire des sujets ayant une consommation de cannabis = 1 jour par semaine) par ...
- Delphine Brault
- Quentin Borie
Dormakaba : Good H2 and Shape4Growth plan bearing fruit
>2023-24: good H2 figures and better-than-expected results - Revenues came in 4.7% higher in organic terms in 2023-24 (css at 4%), with 5.5% for H2. The price effect came to 2.8% and volumes were up 1.9% (with 0.8% in H1 and 3.1% in H2). The adjusted EBITDA margin came in at 14.7% (css at 14.5%), a 120bp improvement on last year. Adjusted EBITDA reached CHF 417m, 2% ahead of consensus expectations. FCF is solid, increasing to CHF 205m. The group is to propose a divide...
- Thijs Berkelder
SIF : Large monopile contract negotiated with winner in UK round 6 auc...
>Additional 140 kt of monopiles for 2026 = 210 kt - Exclusive negotiations. Sif has announced it has engaged in exclusive negotiations for a 140 kt monopile related foundations project, part of the UK’s CfD 6 auction outcome published yesterday. It is expected that a final contract will be reached before the end of 2024. At that moment Sif can share more information on the content of the project. 4.9 GW of UK offshore wind projects were awarded. In UK’s Round 6...
- Delphine Brault
- Quentin Borie
Dormakaba : Un bon S2 et un plan Shape4Growth qui porte ses fruits
>2023/2024 : un bon S2 et des résultats meilleurs qu’attendu - L’activité s’est établie en hausse de 4.7% en organique en 2023/2024 (css à 4%), dont 5.5% pour le seul S2. L’effet prix atteint 2.8% et les volumes sont en hausse de 1.9% (dont 0.8% au S1 et 3.1% au S2). La marge d’EBITDA ajusté s’établit à 14.7% (css à 14.5%), en hausse de 120 pb par rapport à l’année dernière. L’EBITDA ajusté atteint 417 MCHF, 2% au-dessus des attentes du consensus. Le FCF est solide et...
Aelis Farma annonce les résultats de son étude clinique de phase 2B av...
BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), société biopharmaceutique en phase clinique spécialisée dans le développement de traitements pour les maladies du cerveau, annonce les résultats de l’étude clinique de phase 2B réalisée avec AEF01171, évaluant son efficacité et sa sécurité chez des participants en quête de traitement et souffrant d’un trouble modéré à sévère de l’usage de cannabis (CUD), ayant consommé du cannabis au moins ≥5 jours/semaine au moment de l’inclusion dans l’essai. Dans cette étude, 82% des participants souffra...
dormakaba releases 2023/24 Sustainability Report: strong progress in s...
dormakaba Holding AG / Key word(s): Sustainability dormakaba releases 2023/24 Sustainability Report: strong progress in sustainability initiatives 04.09.2024 / 06:30 CET/CEST Rümlang, 4 September 2024 – dormakaba released its ninth annual Sustainability Report, highlighting progress made in the financial year 2023/24 in achieving key environmental, social, and governance (ESG) goals. The company continues to lead in sustainability and has met important milestones on climate change, health and safety, human rights, and product innovation. Key achievements as published in t...
dormakaba veröffentlicht Nachhaltigkeitsbericht 2023/24: starke Fortsc...
dormakaba Holding AG / Schlagwort(e): Nachhaltigkeit dormakaba veröffentlicht Nachhaltigkeitsbericht 2023/24: starke Fortschritte bei Nachhaltigkeitsinitiativen 04.09.2024 / 06:30 CET/CEST Rümlang, 4. September 2024 – dormakaba hat seinen neunten jährlichen Nachhaltigkeitsbericht veröffentlicht, der die Fortschritte im Geschäftsjahr 2023/24 beim Erreichen der wichtigsten Ziele bezogen auf Umwelt, soziale Aspekte sowie Unternehmensführung (ESG – Environmental, Social, Governance) zeigt. Das Unternehmen ist weiterhin führend in Sachen Nachhaltigkeit und hat wichtige Meilenstei...
- Roland Pfaender
- MBA
- CFA
- CCRA
- Steven Gould
- Roland Pfaender
- MBA
- CFA
- CCRA
- Steven Gould
- Delphine Brault
- Quentin Borie
Dormakaba : Robust 2023-24 earnings, the guidance underpins the medium...
>FY 2023-24: Sales up +4.7%, adjusted EBITDA margin +120bp - This morning, the group reported FY 2023-24 results a shade above the consensus. Organic growth stood at 4.7%, slightly above the consensus (4%), of which 5.5% for H2 alone. As a reminder, the group was aiming for organic growth of 3-5%. The 5.5% includes a price effect of 2.8% and therefore a volume effect of 1.9% (of which 0.8% in H1 and 3.1% in H2). In terms of activity, the best performance came (su...
- Delphine Brault
- Quentin Borie
Dormakaba : Résultats 2023/24 solides, la guidance conforte les object...
>FY 2023/24 : CA +4.7%, marge d’EBITDA ajusté +120 pb - Le groupe a publié ce matin des résultats annuels (2023/24) légèrement supérieurs au consensus. La croissance organique s’est établie à 4.7%, légèrement supérieure au consensus (4%), dont 5.5% pour le seul S2. Pour rappel, le groupe visait une croissance organique de 3-5%. Les 5.5% intègrent 2.8% d’effet prix et donc 1.9% de volumes (dont 0.8% au S1 et 3.1% au S2). En termes d’activité, la meilleure performa...
- Jean Danjou
- Oliver Metzger
ETL EUTELSAT COMMUNICATIONS SA
SESGL SES SA FDR (CLASS A)
PROX PROXIMUS SA DE DROIT PUBLIC
KPN ROYAL KPN NV
ORA ORANGE SA
EN BOUYGUES SA
UTDI UNITED INTERNET AG
BLC BASTIDE LE CONFORT MEDICAL SA
GAMA GAMMA COMMUNICATIONS
BON BONDUELLE SCA
DTE DEUTSCHE TELEKOM AG
FIE FIELMANN AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
SIFG SIF HOLDING NV
CLNX CELLNEX TELECOM S.A.
FNTN FREENET AG
AVTX AVANTIUM NV
VOD VODAFONE GROUP PLC
OBEL ORANGE BELGIUM SA
TEF TELEFONICA SA
NFN NFON AG
DRI 1&1 DRILLISCH AG
ECMPA EUROCOMMERCIAL PROPERTIES NV
SCHOTT PHARMA AG
- Jean Danjou
- Oliver Metzger
ETL EUTELSAT COMMUNICATIONS SA
SESGL SES SA FDR (CLASS A)
PROX PROXIMUS SA DE DROIT PUBLIC
KPN ROYAL KPN NV
ORA ORANGE SA
EN BOUYGUES SA
UTDI UNITED INTERNET AG
BLC BASTIDE LE CONFORT MEDICAL SA
GAMA GAMMA COMMUNICATIONS
BON BONDUELLE SCA
DTE DEUTSCHE TELEKOM AG
FIE FIELMANN AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
SIFG SIF HOLDING NV
CLNX CELLNEX TELECOM S.A.
FNTN FREENET AG
AVTX AVANTIUM NV
VOD VODAFONE GROUP PLC
OBEL ORANGE BELGIUM SA
TEF TELEFONICA SA
NFN NFON AG
DRI 1&1 DRILLISCH AG
ECMPA EUROCOMMERCIAL PROPERTIES NV
SCHOTT PHARMA AG
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Indian participation casts shadow over excellent result of core segments. ASML: Spotlight on export restrictions again. Basic-Fit: Dutch parliament persists in plans to raise VAT for oa Sports to 21%. CFE: Earnings quality improved in challenging markets. Eurocommercial Properties: Better numbers, guidance moved toward the higher end of the range. OCI: IFCO sale successfully closed, cash return unlocked Recticel: Solid 1H24 beat, FY guidance may disappoint. SIF Grou...
- Thijs Berkelder
SIF : H1 in-line and new factory on track and on budget
>H1 adj. EBITDA up 22% and FY24 guidance confirmed - Production: 53 monopiles and 64 transition pieces (86 Kton) in foundation numbers more or less similar as 23H1 (52 monopiles and 66 transition pieces) but in steel volume lower (94 Kton).Revenue in H1 2024 up 6% y-o-y to € 231m (AAOB € 113m), implying Q2 revenues of € 124m, up 13% y-o-y after Q1 revenues of € 107m, down 1% y-o-y.Contribution margin up 10% y-o-y to € 78.6m (AAOB € 78.3m), implying Q2 up 20%...
- ING Helpdesk
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.